Clinical Trials Browser

INDUSTRY × Tumor-Agnostic × 30 days × Clear all

NCT04606381 2026-06-05

PALOMA

Phase 1 Active not recruiting

Neoplasms

NCT06178614 2026-06-05

A Study of JNJ-87890387 for Advanced Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT06311578 2026-06-05

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT06901531 2026-06-05

LUCERNA

Phase 3 Recruiting

Adenocarcinoma, Neoplasms

NCT07005102 2026-06-05

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Neoplasms

NCT07525141 2026-06-05

A Study of JNJ-1761981 in Participants With Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT07630974 2026-06-05

MK-9999-01D

Phase 1/2 Not yet recruiting

Neoplasms

NCT06761976 2026-06-04

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Neoplasms

NCT07403721 2026-06-04

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Phase 1 Recruiting

Neoplasm Metastasis

NCT03899155 2026-06-03

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT07247110 2026-06-03

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

Phase 1 Recruiting

Neoplasms

NCT07620951 2026-06-03

Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China

Phase 1 Not yet recruiting

Neoplasm Metastasis

NCT03435796 2026-06-02

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Phase 2/3 Recruiting

Neoplasms

NCT07621471 2026-06-02

IL-15 Enhanced NK Cell Therapy for Solid Tumors

Phase EARLY_PHASE1 Not yet recruiting

Neoplasm Metastasis

NCT06183151 2026-06-01

CaVe

Neoplasms

NCT07213817 2026-06-01

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07213830 2026-06-01

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT00463814 2026-05-29

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

Phase 1 Active not recruiting

Neoplasms

NCT04145622 2026-05-29

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Phase 1/2 Recruiting

Neoplasms

NCT04401020 2026-05-29

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Phase 1 Completed

Neoplasms

NCT05365581 2026-05-28

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Phase 1 Recruiting

Adenocarcinoma

NCT05396833 2026-05-28

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT06246110 2026-05-28

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT06593522 2026-05-28

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

Phase 2 Active not recruiting

Neoplasms

NCT07335497 2026-05-28

ASCEND

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07612176 2026-05-28

A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

Phase 1 Recruiting

Neoplasm Metastasis, Neoplasms

NCT07612488 2026-05-28

A Study of CS231295 in Patients With Advanced Solid Tumors

Phase 1 Not yet recruiting

Neoplasms

NCT04958239 2026-05-27

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

Phase 1 Active not recruiting

Neoplasms

NCT05384626 2026-05-27

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07438782 2026-05-27

First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT07193511 2026-05-26

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07209111 2026-05-26

KANDLELIT-014

Phase 2 Recruiting

Neoplasms

NCT05673018 2026-05-22

Galleri® in the Medicare Population.

Phase NA Recruiting

50,000 enrolled

Neoplasms

NCT06431594 2026-05-22

BEHOLD-1

Phase 1 Recruiting

Neoplasms

NCT06551142 2026-05-22

PanTumor-101

Phase 1 Recruiting

Neoplasms

NCT06589310 2026-05-22

Falcon Real World Evidence Registry

25,000 enrolled

Neoplasms

NCT06796907 2026-05-22

BEHOLD-2

Phase 1/2 Recruiting

Neoplasms

NCT06803680 2026-05-22

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Neoplasm Metastasis

NCT07600749 2026-05-22

Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

Phase 1 Not yet recruiting

Neoplasms

NCT00750841 2026-05-19

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT04130542 2026-05-19

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Phase 1 Completed

Neoplasms

NCT04635995 2026-05-19

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

Phase 1 Completed

Neoplasms

NCT05303532 2026-05-19

ROSY-D

Phase 3 Enrolling by invitation

Neoplasms

NCT06883058 2026-05-18

CASA

Phase NA Enrolling by invitation

Neoplasms